

REMARKS

I. Status of the Claims

Claims 16-21 are under examination. Claims 16-20 are allowable, and claim 21 is are rejected under 35 U.S.C. §112, first paragraph and under the judicially-created doctrine of obviousness-type double-patenting. The detailed basis for the rejections, and applicants' response thereto, are set out below.

II. Rejection Under 35 U.S.C. §112, First Paragraph

Examiner rejects claim 21 under 35 U.S.C. §112, first paragraph, asserting that “applicant was not in possession of the genus of antibodies having an increased serum half-life, when obtained by the process of base claim 16.” Applicants again traverse for the reasons of record, but the claim has been canceled to further prosecution.

III. Rejection for Obviousness-Type Double-Patenting


Claim 21 is rejected under the judicially-created doctrine of obviousness-type double-patenting. As claim 21 now has been canceled, the rejection is moot.

IV. Conclusion

In light of the foregoing, applicants respectfully submit that all claims are in condition for allowance, and an early notification to that effect is earnestly solicited. Examiner is invited to contact the undersigned at (512) 536-3184 with any questions, comments or suggestions relating to the referenced patent application.

Please date stamp and return the enclosed postcard as evidence of receipt.

Respectfully submitted,



Steven L. Highlander, Esq.
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 536-3184

Date: April 15, 2004